Other Authors have highlighted the promising use of anti-CD38 antibodies in CRC patients refractory to other therapies, nonetheless no clinical trials or approvals have been proposed for CRC, even though anti-CD38 antibodies have represented a break-through in multiple myeloma (Nooka et al., 2019) and are at present approved in this indication. Here, CD38 is linked to plasma cell myeloma.